Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

Background We compared docetaxel with vinorelbine for the adjuvant treatment of early breast
cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive …

Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based
chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free
survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) …

Background Few effective treatments exist for patients with advanced urothelial carcinoma
that has progressed after platinum-based chemotherapy. We assessed the activity and safety …

Purpose Docetaxel has not been compared with vinorelbine as adjuvant treatment of early
breast cancer. Efficacy and long-term safety of a short course of adjuvant trastuzumab …

Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as
additional conduits for metastatic spread. The identification of growth factor receptor …

Purpose To determine the clinical efficacy of imatinib in patients with advanced aggressive
fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent. …

Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell
surface expression is induced under inflammatory conditions. It has been shown previously to …

9520 Background: Signaling via LAG-3 and other T-cell inhibitory receptors (eg, PD-1) can
lead to T-cell dysfunction and tumor immune escape. Simultaneous blockade of LAG-3 + PD-…